Skip to main content
SpringerLink
Log in

HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer

  • Chapter
Polymer Drugs in the Clinical Stage

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 519))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Oriel KA, Hartenbach EM, Remington PL. Trends in United States ovarian cancer mortality: 1979–1995. Obstet Gynecol 93:30–33 (1999).

    Article  PubMed  CAS  Google Scholar 

  2. NIH Consensus Development Panel. Ovarian cancer: Screening, treatment, and followup. JAMA 273:491–497 (1995).

    Google Scholar 

  3. Wolff BE, Sugarbaker RH. Intraperitoneal chemotherapy and immunotherapy. Recent Res Cancer Res 110:254–273 (1988).

    Google Scholar 

  4. Brenner DE. lntraperitoneal chemotherapy: A review. J Clin Oncol 4:1135–1147 (1986).

    PubMed  CAS  Google Scholar 

  5. Yong RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 250:3072 (1983).

    Google Scholar 

  6. Berek J. Epithelial ovarian cancer. In: Practical Gynecological Oncology, Berek JS, Hacker NS (eds), Williams and Wilkins, Philadelphia, PA, 366 (1994).

    Google Scholar 

  7. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. Br Med J 9:89 (1991).

    Google Scholar 

  8. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and ciplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 9:1668 (1991).

    Google Scholar 

  9. Williams CJ. Implications of an Overview of Chemotherapy in Advanced Ovarian Carcinoma. Br J Cancer 66:225–6 (1992)

    PubMed  CAS  Google Scholar 

  10. Putnam D, Kopecek J. Polymer conjugates with anticancer activity. Adv Polym Sci 122:55–123(1995).

    CAS  Google Scholar 

  11. Reynolds T. Polymers Help Guide Cancer Drugs to Tumor Targets-Keep Them There. J Natl Cancer Inst 87:1582 (1995).

    PubMed  CAS  Google Scholar 

  12. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherpay: mechanisms of tumoritropic accumulation of proteins and antitumor agent SMANCS. Cancer Res 6:6387 (1986).

    Google Scholar 

  13. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307–14 (1998).

    PubMed  CAS  Google Scholar 

  14. Shiah J-G, Sun Y, Peterson CM, Kopeček J. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer bound mesochlorin e 6 and adriamycin in nude Mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Contr Rel 61:145–57 (1999)

    Article  CAS  Google Scholar 

  15. Seymour LW, Ulbrich K, Strohalm J, Kopeček J. The pharmacokinetics of polymerbound adriamycin, Biochem Pharmacol 39:1125–30 (1990)

    Article  PubMed  CAS  Google Scholar 

  16. ai]16. Remanová P, Kopeček J, Duncan R, Lloyd JB. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide) copolymers. Biomaterials 6:45–48 (1985).

    Google Scholar 

  17. Simekova J, Plocova, Řihová, B, Kopeček J. Activation of complement in the presence of in N-(2-hydroxypropyl)methacrylamide) copolymers. J Bioact Comp Polym 1:20–31 (1986).

    Google Scholar 

  18. Lloyd JB, Duncan R, Kopeček J. Synthetic polymers as targetable carriers for drugs. Pure Appl Chem 56:1301–1304 (1984).

    CAS  Google Scholar 

  19. Kopeček J. Controlled degradability of polymers-a key to drug delivery systems. Biomaterials 5:19–25 (1984).

    PubMed  Google Scholar 

  20. Omelyanenko V, Kopečeková P, Gentry C, Kopeček J. Targetable HPMA copolymeradriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Rel 53:25–37 (1998).

    CAS  Google Scholar 

  21. Slobbe R, Poels L, ten Dam G, Boerman O, Nieland L, Leunissen J, Ramaekers F, VanEys G. Analysis of idiotype structure of ovarian cancer antibodies: Recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences. Clin Exp Immunot 98:95–103 (1994).

    CAS  Google Scholar 

  22. Li S, Deshrnukh HM, Huang L Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res 15:1540–1545 (1998).

    PubMed  CAS  Google Scholar 

  23. Maeda H, Seymour LM, Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug Chem 3:351–362 (1992).

    Article  PubMed  CAS  Google Scholar 

  24. Duncan R. Drug-polymer conjugates:potential for improved chemotherapy. Anticancer Drugs 3:175–210 (1992).

    PubMed  CAS  Google Scholar 

  25. Řihova R, Kopeček J, Ulbrich K, Chytry V. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers. Makromol Chem Suppi 9:13–24 (1985).

    Google Scholar 

  26. Cuvier C, Robot-Treupel L, Millot JM, Lizard G, Chevillard S, Manfait M, Couvreur P, Poupon MF. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharm 44:509–517 (1992).

    Article  PubMed  CAS  Google Scholar 

  27. Bodley AL, Liu LF. Topoisomerase as novel targets for cancer chemotherapy. Biotechnology 6:1315–1319 (1988).

    CAS  Google Scholar 

  28. Denny WA. DNA-intercalating ligands as anticancer drugs: prospects for future design. Anti-Cancer Drug Des 4:241–249 (1989).

    CAS  Google Scholar 

  29. Bristow MR, Billingham ME, Masson JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873–878 (1978).

    PubMed  CAS  Google Scholar 

  30. Lefrak EA, Pitha J, Rosenheim S, O’Bryan RM, Burgess MA, Gottlieb JA. Adriamycin (NSC 123127) cardiomyopathy. Cancer Chemother Rep 6:203–208 (1975).

    Google Scholar 

  31. Ogura R, Sugiyama M, Haramaki N, Hidaka T. Electron spin resonance studies on the mechanism of Adriamycin-induced heart mitochondrial damages. CancerRes 51:3555–3558 (1991).

    CAS  Google Scholar 

  32. Lu JM, Peterson CM Sun Y, Peterson CA, Shiah J-G, Straight RC, Kopeček J. Cooperativity between free and N-(2-hydroxypropyl)methacrylamide copolymer bound adriamycin and mesochlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro. Int J Oncol 15:5–16 (1999).

    PubMed  CAS  Google Scholar 

  33. Peterson CM, Lu JM, Sun Y, Peterson CA, Shiah JG, Straight RC, Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Clin Cancer Res 56:83–94 (1999).

    Google Scholar 

  34. Duncan R, Kopečeková P, Strohalm J, Hume IC, Lloyd JB, Kopeček J. Anticancer agents coupled to N-(2-hydroxyprophyl)methacrylamide copolymers 2. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Brit J Cancer 57:147–156 (1988).

    PubMed  CAS  Google Scholar 

  35. Vasey P, Twelves C, Kaye S, Wilson P, Morrison R, Duncan R, Thomson A, Hilditch T, Murray T, Burtles S, Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents: drugpolymer conjugates. Clin Cancer Res 5:83–94 (1999).

    PubMed  CAS  Google Scholar 

  36. Minko T, Kopečeková P, Kopeček J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res 16:986–996(1999).

    Article  PubMed  CAS  Google Scholar 

  37. Seymour LW, Duncan R, Strohalm J, Kopeček J. Effect of molecular weight (Mw) of of N-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J J Biomed Mater Res 21:1341–58 (1987).

    CAS  Google Scholar 

  38. Řihová B, Ulbrich K, Kopeček J, Mančal P. The immunogenicty of N-(2-hydroxypropyl) methacrylamide copolymers-potential hapten or drug carriers. Folia Microbiol 28:217–27 (1983).

    Google Scholar 

  39. Řihová B, Kopeček J, Ulbrich K, Pospišil M, Mančal P. Effect of the chemical structure of N-(2-hydroxypropyl) methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 5:143–8 (1984).

    PubMed  Google Scholar 

  40. Řihová B, Kopeček J, Ulbrich K, Chytry V. Immunogenicity of N-(2-hydroxypropyl) methacrylamide copolymers. Makromol. Chem Supl 9:13–24 (1995).

    Google Scholar 

  41. Simeckova J, Řiihová B, Plocova D, Kopeček J. Activity of complement in the presence of N-(2-hydroxypropyl) methacrylamide copolymers. J Bioact Compat Polymers 1:20–31 (1986).

    CAS  Google Scholar 

  42. Řihová B, Bilej M, Věetvička V. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing doxorubicin. Biomaterials. 10:335–42 (1989).

    PubMed  Google Scholar 

  43. Vasey PA, Duncan R, Kaye SB, Cassidy J. Phase 1 clinical and pharmacokinetic study of PK1 (N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug polymer conjugates. EROTC Abstract

    Google Scholar 

  44. Duncan R, Seymour LW, O’Hare KB, Flanagan PA, Wedge S, Ulbrich K, Strohalm J, Subr V, Spreafico F, Grandi M, Ripamonti M, Farao M, Suarato A. Preclinical evaluation of polymer bound doxorubicin. J Controlled Rel 19:331–46 (1992).

    Article  CAS  Google Scholar 

  45. Thomson AH, Vasey PA, Murray LS, Cassidy J, Fraier D, Frigerio E, Twleves C. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumors. Br J Ca 81:99–107 (1999).

    CAS  Google Scholar 

  46. Loadman PM, Bibby MC, Double JA, Al-Shakhaa WM, Duncan R. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin Cancer Res 5:3682–8(1999)

    PubMed  CAS  Google Scholar 

  47. Peterson CM, Reed R, Jolles CJ, Jones KP, Straight RC, Poulson AM. Photodynamic therapy of human ovarina epithelial carcinoma, OVCAR-3, heterotransplanted in the nude mouse. Am J Obstet Gynecol 167:1852–5 (1992).

    PubMed  CAS  Google Scholar 

  48. Chaplin DJ. The effect of photodynamic therapy on tumor vascular function. Int J Radial Biol 60:311–325 (1991).

    CAS  Google Scholar 

  49. Feyh J, Goetz A, Heiman A, Konigsberger R, Kastenbauer E. Microcirculatory effects of photodynamic therapy with hematoporphyrin derivative. Laryngo-Rhino-Otol 70:99–101 (1991).

    CAS  Google Scholar 

  50. Moan J. Porphyrin-sensitized photodynamic inactivation of cells: A review. Lasers Med Sci 1:5–12 (1986).

    Article  Google Scholar 

  51. Kennedy JC, Nadeau P, Petryka ZJ, Pottier RH, Weagle G. Clearance times of photophyrin derivatives from mice as measured by in vivo fluorescence spectroscopy. Photochem Photobiol 55:729–734 (1992).

    PubMed  CAS  Google Scholar 

  52. Shiah J-G, Koňák Č, Spikes JD, Kopeček J. Influence of pH on aggregation and photoproperties of N-(2-hydroxypropyl)methacrylamide copolymer-meso chlorin e6 conjugates. Drug Delivery 5:119–26 (1998)

    Article  CAS  PubMed  Google Scholar 

  53. Brophy PF, Keller SM. Adriamycin enhanced in vitro and in vivo photodynamic therapy of mesothelioma. J Surg Res 52:631–634 (1992).

    Article  PubMed  CAS  Google Scholar 

  54. Peterson CM, Lu JM, Gu ZW, Shiah JG, Lythgoe K, Peterson CA, Straight RC, Kopeček J. lsobolographic assessment between adriamycin and photodynamic therapy with meso-chlorin e 6 monoethylene diaamine in human ovarian carcinoma (OVCAR-3) in vivo. J Soc Gynecol Invest 2:772–777 (1995).

    CAS  Google Scholar 

  55. Shiah J-G, Sun Y, Peterson CM, Straight RC, Kopeček J. Antitumor activity of HPMA copolymer mesochlorin e 6 and adriamycin in combination treatments. Clin Cancer Res 6:1008–15 (2000).

    PubMed  CAS  Google Scholar 

  56. Krinick NL, Sun Y, Joyner D, Spikes JD, Straight RC, Kopeček J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J Biomat Sci, Polym Ed 5:303–324 (1994).

    CAS  Google Scholar 

  57. Minko T, Kopečekova, Kopeček J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer 86:108–17(2000).

    Article  PubMed  CAS  Google Scholar 

  58. Minko T, Kopečeková P, Pozharov V, Jensen KD, Kopeček J. The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability and retention effect in resistant solid tumor. Pharm Res 17:505–14 (2000).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Obstetrics and Gynecology, Pharmaceutics and Pharmaceutical Chemistry, Utah. Center for Photo-Medicine, University of Utah and the Veteran’s Administration Medical Center, Salt Lake City, Utah, USA

    C. Matthew Peterson, Jane-Guo Shiah, Yongen Sun, Pavla KopeČKovÁ, Tamara Minko, Richard C. Straight & Jindrich KopeČEk

Authors
  1. C. Matthew Peterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane-Guo Shiah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yongen Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pavla KopeČKovÁ
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tamara Minko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard C. Straight
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jindrich KopeČEk
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kumamoto University School of Medicine, Kumamoto, Japan

    Hiroshi Maeda

  2. University of Nebraska Medical Center, Omaha, Nebraska

    Alexander Kabanov

  3. University of Tokyo, Tokyo, Japan

    Kazunori Kataoka

  4. Tokyo Women’s Medical College, Tokyo, Japan

    Teruo Okano

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Peterson, C.M. et al. (2004). HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer. In: Maeda, H., Kabanov, A., Kataoka, K., Okano, T. (eds) Polymer Drugs in the Clinical Stage. Advances in Experimental Medicine and Biology, vol 519. Springer, Boston, MA. https://doi.org/10.1007/0-306-47932-X_7

Download citation

  • DOI: https://doi.org/10.1007/0-306-47932-X_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-47471-2

  • Online ISBN: 978-0-306-47932-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation